Wire · opportunities
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Abbott received FDA authorization for the Libre Duo 10 Day, the first biowearable device that simultaneously monitors glucose and ketone levels to help prevent diabetic ketoacidosis in people with diabetes. The device integrates with leading diabetes apps and automated insulin delivery systems and targets patients at higher risk of elevated ketones.
This Wire brief sits within Fusion42's coverage of Health: Medtech, and 4 sources have reported it between 25 Aug 2026 and 26 Aug 2026.
◆ ◆ The Wire takeaway
You must update your diabetes care offerings to integrate continuous ketone monitoring alongside glucose tracking or risk losing patients to Abbott's newly FDA-approved device. This dual sensor sets a new clinical standard that will pressure competitors to add ketone alerts in real time.
◆ Coverage
4 sources · first reported 25 Aug 2026 · latest 26 Aug 2026
◆ Related on Wire
◆ Topics